[1] Kimoto, Y. (1998) Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes, Chromosomes and Cancer, 22, 83-86. doi:10.1002/(SICI)1098-2264(1998)22:1<83::AID-GCC12>3.0.CO;2-O
[2] Li, J., Tan, C., Xiang, Q., Zhang, X., Ma, J., Wang, J.-R., et al. (2001) Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. Journal of Protein Chemistry, 20, 265-271. doi:10.1023/A:1010912311564
[3] Qiu, X., Zhu, X., Zhang, L., Mao, Y., Zhang, J., Hao, P., et al. (2003) Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Research, 63, 6488- 6495. http://cancerres.aacrjournals.org/content/63/19/6488.abstract
[4] Li, M., Feng, D.-Y., Ren, W., Zheng, L., Zheng, H., Tang, M., et al. (2004) Expression of immunoglobulin kappa light chain constant region in abnormal human cervical epithelial cells. International Journal of Biochemistry and Cell Biology, 36, 2250-2257. doi:10.1016/j.biocel.2004.03.017
[5] Babbage, G., Ottensmeier, C., Blaydes, J., Stevenson, F., and Sahota, S. (2006) Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Research, 66, 3996-4000. doi:10.1158/0008-5472.CAN-05-3704
[6] Chen, Z. and Gu, J. (2007) Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB Journal, 21, 2931-2938. doi:10.1096/fj.07-8073com
[7] Zheng, H., Li, M., Liu, H., Ren, W., Hu, D.-S., Shi, Y., et al. (2007) Immunoglobulin alpha heavy chain derived from human epithelial cancer cells promotes the access of S phase and growth of cancer cells. Cell Biology International, 31, 82-87. doi:10.1016/j.cellbi.2006.09.009
[8] Zheng, H., Li, M., Ren, W., Zeng, L., Liu, H.-D., Hu, D., et al. (2007) Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Molecular Immunology, 44, 2221-2227. doi:10.1016/j.molimm.2006.11.010
[9] Huang, J., Sun, X., Mao, Y., Zhu, X., Zhang, P., Zhang, L., et al. (2008) Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse brain neurons. International Journal of Biochemistry and Cell Biology, 40, 1604-1615. doi:10.1016/j.biocel.2007.12.004
[10] Lee, G., Laflamme, E., Chien, C.-H. and Ting, H.H. (2008) Molecular identity of a pan cancer marker, CA215. Cancer Biology and Therapy, 7, 2007-2014. doi:10.4161/cbt.7.12.6984
[11] Zhu, X., Li, C., Sun, X., Mao, Y., Li, G., Liu, X., et al. (2008) Immunoglobulin mRNA and protein expression in human oral epithelial tumor cells. Applied Immunohistochemistry & Molecular Morphology, 16, 232-238. doi:10.1097/PAI.0b013e31814c915a
[12] Huang, J., Zhang, L., Ma, T., Zhang, P. and Qiu, X. (2009) Expression of immunoglobulin gene with classical V-(D)- J rearrangement in mouse testis and epididymis. Journal of Histochemistry and Cytochemistry, 57, 339-349. doi:10.1369/jhc.2008.951434
[13] Lee, G. and Ge, B. (2009) Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomarkers, 5, 177-188.
[14] Zheng, J., Huang, J., Mao, Y., Liu, S., Sun, X., Zhu, X., et al. (2009) Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. Journal of Biological Chemistry, 284, 13610- 13619. doi:10.1074/jbc.M809524200
[15] Zhang, S., Mao, Y., Huang, J., Ma, T., Zhang, L., Zhu, X., et al. (2010) Immunoglobulin gene locus events in epithelial cells of lactating mouse mammary glands. Cellular and Molecular Life Sciences, 67, 985-994. doi:10.1007/s00018-009-0231-z
[16] Hu, D., Duan, Z., Li, M., Jiang, Y., Liu, H., Zheng, H., et al. (2011) Heterogeneity of aberrant immunoglobulin expression in cancer cells. Cellular and Molecular Immunology, 8, 479-485. doi:10.1038/cmi.2011.25
[17] Zhang, L., Hu, S., Korteweg, C., Chen, Z., Qiu, Y., Su, M., et al. (2012) Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Human Pathology, 43, 423- 434. doi:10.1016/j.humpath.2011.05.020
[18] Hu, F., Zhang, L., Zheng, J., Zhao, L., Huang, J., Shao, W., et al. (2012) Spontaneous production of immunoglobulin M in human epithelial cancer cells. PLoS ONE, 7, e51423. doi:10.1371/journal.pone.0051423
[19] Li, M., Zheng, H., Duan, Z., Liu, H., Hu, D., Bode, A., et al. (2012) Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. Cellular & Molecular Immunology, 9, 54-61. doi:10.1038/cmi.2011.40
[20] Lee, C.Y., Chen, K.W., Sheu, F.S., Tsang, A., Chao, K.C., and Ng, H.T. (1992) Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. Cancer Immunology, Immunotherapy, 35, 19-26. doi:10.1007/BF01741050
[21] Lee, G., Wu, Q., Li, C. H., Ting, H.H. and Chien, C.-H. (2006) Recent studies of a new carbohydrate-associated pan cancer marker, CA215. Journal of Clinical Ligand Assay, 29, 47-51. doi:10.4161/cbt.7.12.6984
[22] Lee, G., Zhu, M., Ge, B. and Potzold, S. (2012) Widespread expressions of immunoglobulin superfamily proteins in cancer cells. Cancer Immunology, Immunotherapy, 61, 89-99. doi:10.1007/s00262-011-1088-1
[23] Lee, G. and Azadi P. (2012) Peptide mapping and glycoanalysis of cancer cell-expressed glycoproteins CA215 recognized by RP215 monoclonal antibody. Journal of Carbohydrate Chemistry, 31, 10-30. doi:10.1080/07328303.2011.626544
[24] Lee, G., Ge, B., Huang, T.-K., Zheng, G., Duan, J. and Wang, I.H.Y. (2009) Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomarkers, 6, 111-117.
[25] Lee, G., Zhu, M., Ge, B., Cheung, A. P., Chien, C.-H., Chow, S.-N., et al. (2012) Carbohydrate-associated immunodominant epitope(s) of CA215. Immunological Investigations, 41, 317-336. doi:10.3109/08820139.2011.633141
[26] Qiu, X., Liu, W. and Lee, G. (2013) The application of RP215 monoclonal antibody in the study of proliferation, migration, chemo-resistance, of cancer cells as well as cancer stem cells. Chinese Patent No. 201110211923.8.
[27] Lee, G., Cheung, A., Ge, B., Zhu, M., Giolma, B., Li, B., et al. (2012) CA215 and GnRH receptor as targets for cancer therapy. Cancer Immunology, Immunotherapy, 1- 13. doi:10.1007/s00262-012-1230-8
[28] Tang, Y., Zhang, H. and Lee, G. (2013) Similar gene regulation patterns for growth inhibition of cancer cells by RP215 or anti-antigen receptors. Journal of Cancer Science and Therapy, 5, 200-208. doi:10.4172/1948-5956.1000207
[29] So, E.Y. and Ouchi, T. (2010) The application of toll like receptors for cancer therapy. International Journal of Biological Sciences, 6, 675-681. doi:10.7150/ijbs.6.675
[30] Hu, D., Zheng, H., Liu, H., Li, M., Ren, W., Liao, W., et al. (2008) Immunoglobulin expression and its biological significance in cancer cells. Cellular and Molecular Immunology, 5, 319-324. doi:10.1038/cmi.2008.39
[31] Chen, Z., Qiu, X. and Gu, J. (2009) Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. American Journal of Pathology, 174, 1139-1148. doi:10.2353/ajpath.2009.080879
[32] Lee, G. (2012) Cancerous immunoglobulins and CA215: Implications in cancer immunology. American Journal of Immunology, 8, 101-116. http://0.3844/ajisp.2012.101.116
[33] Chen, Z., Huang, X., Ye, J., Pan, P., Cao, Q., Yang, B., et al. (2010) Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. Cancer, 116, 1953-1963. doi:10.1002/cncr.24892
[34] Liu, Y., Chen, Z., Niu, N., Chang, Q., Deng, R., Korteweg, C., et al. (2012) IgG gene expression and its possible significance in prostate cancers. The Prostate, 72, 690-701. doi:10.1002/pros.21476
[35] Niu, N., Zhang, J., Guo, Y., Zhao, Y., Korteweg, C. and Gu, J. (2011) Expression and distribution of immunoglobulin G and its receptors in the human nervous system. International Journal of Biochemistry and Cell Biology, 43, 556-563. doi:10.1016/j.biocel.2010.12.012
[36] Niu, N., Zhang, J., Huang, T., Sun, Y., Chen, Z., Yi, W., et al. (2012) IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One, 7, e47362. doi:10.1371%2Fjournal.pone.0047362
[37] Niu, N., Zhang, J., Wang, S., Sun, Y., Korteweg, C., Gao, W., et al. (2011) Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: The eye. Cellular and Molecular Life Sciences, 68, 2481-2492. doi:10.1007/s00018-010-0572-7
[38] Qiu, Y., Korteweg, C., Chen, Z., Li, J., Luo, J., Huang, G., et al. (2012) Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Modern Pathology, 25, 36-45. doi:10.1038/modpathol.2011.139
[39] Zhao, Y., Liu, Y., Chen, Z., Korteweg, C. and Gu, J. (2011) Immunoglobulin G (IgG) expression in human umbilical cord endothelial cells. Journal of Histochemistry and Cytochemistry, 59, 474-488. http://jhc.sagepub.com/content/59/5/474.abstract
[40] Zhu, X., Wu, L., Zhang, L., Hao, P., Zhang, S., Huang, J., et al. (2010) Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cellular Molecular Immunology, 7, 279-286. doi:10.1038/cmi.2010.13
[41] Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y. and Honjo, T. (2000) Class switch recombinetion and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell, 102, 553-563. doi:10.1016/S0092-8674(00)00078-7
[42] Papavasiliou, F.N. and Schatz, D.G. (2002) Somatic hypermutation of immunoglobulin genes: Merging mechanisms for genetic diversity. Cell, 109, S35-S44. doi:10.1016/S0092-8674(02)00706-7
[43] Honjo, T., Kinoshita, K. and Muramatsu M. (2002) Molecular mechanism of class switch recombination: Linkage with somatic hypermutation. Annual Review of Immunology, 20, 165-196. doi:10.1146/annurev.immunol.20.090501.112049
[44] Lee, G., Cheung, A.P., Li, B., Ge, B. and Chow, P.-M. (2012) Molecular and immuno-characteristics of immunoglobulin-like glycoproteins in cancer cell-expressed biomarker, CA215. Immunological Investigations, 41, 429-446. doi:10.3109/08820139.2012.661007
[45] Chu, P.G. and Weiss, L.M. (2002) Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohisto- chemical study of 509 cases. Modern Pathology, 15, 6-10. doi:10.1038/modpathol.3880483
[46] Lee, G., Zhu, M. and Ge, B. (2012) Potential monoclonal antibody therapy for the treatment of ovarian cancer. In: Farghaly, S.A., Ed., Ovarian Cancer-Basic Science Perspective, InTech, Vancouver, 385-406. doi:10.5772/27471
[47] Lee, G. and Ge, B. (2010) Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunology, Immunotherapy, 59, 1347-1356. doi:10.1007/s00262-010-0864-7
[48] Koropatnick, T.A., Engle, J.T., Apicella, M.A., Stabb, E.V., Goldman, W.E. and McFall-Ngai, M.J. (2004) Microbial factor-mediated development in a host-bacterial mutualism. Science, 306, 1186-1188. doi:10.1126/science.1102218
[49] O’Neill, L.A.J. (2008) Toll-like receptors in cancer. Oncogene, 27, 158-160. doi:10.1038/sj.onc.1210903
[50] O’Neill, L.A., Bryant, C.E. and Doyle, S.L. (2009) Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacological Reviews, 61, 177-197. doi:10.1124/pr.109.001073
[51] Rakoff-Nahoum, S. and Medzhitov, R. (2009) Toll-like receptors and cancer. Nature Reviews. Cancer, 9, 57-63.
[52] Cook, D.N., Pisetsky, D.S. and Schwartz, D.A. (2004) Toll-like receptors in the pathogenesis of human disease. Nature Immunology, 5, 975-979.
[53] Morikawa, T., Sugiyama, A., Kume, H., Ota, S., Kashima, T., Tomita, K., et al. (2007) Identification of toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clinical Cancer Research, 13, 5703-5709. doi:10.1158/1078-0432.CCR-07-0603
[54] Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D. and Romero, P. (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clinical Cancer Research, 13, 4565-4574. doi:10.1158/1078-0432.CCR-07-0274
[55] Yang, H., Zhou, H., Feng, P., Zhou, X., Wen, H., Xie, X., et al. (2010) Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. Journal of Experimental and Clinical Cancer Research, 29, 92. doi:10.1186/1756-9966-29-92
[56] Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A.J., Branscheid, D., Vollmer, E., et al. (2005) Human lung cancer cells express functionally active toll-like receptor 9. Respiratory Research, 6, 1. doi:10.1186/1465-9921-6-1
[57] Ilvesaro, J.M., Merrell, M.A., Swain, T.M., Davidson, J., Zayzafoon, M., Harris, K.W., et al. (2007) Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-781. doi:10.1002/pros.20562
[58] Merrell, M.A., Ilvesaro, J.M., Lehtonen, N., Sorsa, T., Gehrs, B., Rosenthal, E., et al. (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Molecular Cancer Research, 4, 437-447. doi:10.1158/1541-7786.MCR-06-0007
[59] Salaun, B., Coste, I., Rissoan, M.C., Lebecque, S.J. and Renno, T. (2006) TLR3 can directly trigger apoptosis in human cancer cells. Journal of Immunology, 176, 4894- 4901. http://www.jimmunol.org/content/176/8/4894
[60] O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C.M., Arthur, C., White, J.M., et al. (2012) Cancer immunoediting by the innate immune system in the absence of adaptive immunity. The Journal of Experimental Medicine, 209, 1869-1882. doi:10.1084%2Fjem.20112738
[61] Sato, Y., Goto, Y., Narita, N. and Hoon, D.S. (2009) Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenvironment, 2, 205-214. doi:10.1007%2Fs12307-009-0022-y
[62] Lee, J.W., Choi, J.J., Seo, E.S., Kim, M.J., Kim, W.Y., Choi, C.H., et al. (2007) Increased toll-like receptor 9 expression in cervical neoplasia. Molecular Carcinogenesis, 46, 941-947.
[63] Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.-A., Abrahams, V.M., Chan, S., et al. (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research, 66, 3859-3868. doi:10.1158/0008-5472.CAN-05-3948
[64] Nishimura, M. and Naito, S. (2005) Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biological and Pharmaceutical Bulletin, 28, 886-892. doi:10.1248/bpb.28.886
[65] Kim, W.Y., Lee, J.W., Choi, J.J., Choi, C.H., Kim, T.J., Kim, B.G., et al. (2008) Increased expression of toll-like receptor 5 during progression of cervical neoplasia. International Journal of Gynecological Cancer, 18, 300- 305. doi:10.1111/j.1525-1438.2007.01008.x
[66] Huang, B., Zhao, J., Li, H., He, K.L., Chen, Y., Chen, S.H., et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research, 65, 5009-5014. doi:10.1158/0008-5472.CAN-05-0784
[67] Zhou, M., McFarland-Mancini, M.M., Funk, H.M., Husseinzadeh, N., Mounajjed, T. and Drew, A.F. (2009) Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunology, Immunotherapy, 58, 1375- 1385. doi:10.1007/s00262-008-0650-y
[68] Li, Q., Withoff, S. and Verma, I.M. (2005) Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends in Immunology, 26, 318-325. doi:10.1016/j.it.2005.04.003
[69] Griffin, J.D. (2001) Leukemia stem cells and constitutive activation of NF-kappaB. Blood, 98, 2291. doi:10.1182/blood.V98.8.2291a
[70] Xie, W., Wang, Y., Huang, Y., Yang, H., Wang, J. and Hu, Z. (2009) Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochemical and Biophysical Research Communications, 379, 1027-1032. doi:10.1016/j.bbrc.2009.01.009
[71] Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.
[72] So, E.Y. and Ouchi, T. (2010) The application of toll like receptors for cancer therapy. International Journal of Biological Sciences, 6, 675-681. doi:10.7150/ijbs.6.675
[73] Vesely, M.D., Kershaw, M.H., Schreiber, R.D. and Smyth, M.J. (2011) Natural innate and adaptive immunity to cancer. Annual Review of Immunology, 29, 235-271. doi:10.1146/annurev-immunol-031210-101324
[74] Schmausser, B., Andrulis, M., Endrich, S., Muller-Hermelink, H.K. and Eck, M. (2005) Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: An implication for interaction with Helicobacter pylori. International Journal of Medical Microbiology, 295, 179- 185. doi:10.1016/j.ijmm.2005.02.009
[75] Furrie, E., Macfarlane, S., Thomson, G. and Macfarlane, G.T. (2005) Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology, 115, 565-574. doi:10.1111%2Fj.1365-2567.2005.02200.x
[76] Huang, B., Zhao, J., Unkeless, J.C., Feng, Z.H. and Xiong, H. (2008) TLR signaling by tumor and immune cells: A double-edged sword. Oncogene, 27, 218-224. doi:10.1038/sj.onc.1210904
[77] O’Neill, L.A. (2004) TLRs: Professor Mechnikov, sit on your hat. Trends in Immunology, 25, 687-693. doi:10.1016/j.it.2004.10.005.